Mikael Soucisse1, Joseph C Kong2,3,4, Michael Michael5,6, Jeanne Tie5,6, Samuel Y Ngan5,7, Trevor Leong5,7, Jacob McCormick1, Satish K Warrier1,8,5, Alexander G Heriot1,8,5. 1. Division of Cancer Surgery, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia. 2. Division of Cancer Surgery, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia. joekong@gmail.com. 3. Division of Cancer Research, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia. joekong@gmail.com. 4. Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, VIC, Australia. joekong@gmail.com. 5. Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, VIC, Australia. 6. Division of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia. 7. Division of Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia. 8. Division of Cancer Research, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.
Abstract
BACKGROUND: Total neoadjuvant therapy in rectal cancer refers to the administration of chemoradiotherapy plus chemotherapy before surgery. Recent studies have shown improved pathological complete response and disease-free survival with this approach. However, survival benefits remain unproven. Our objective is to present a metaanalysis of oncological outcomes of total neoadjuvant therapy in locally advanced rectal cancer. PATIENTS AND METHODS: A comprehensive search was performed on PubMed, Medline, and Google Scholars. Studies comparing total neoadjuvant therapy with standard neoadjuvant chemoradiotherapy were included. Data extracted from the individual studies were pooled and a metaanalysis performed. The outcomes of interest are the rate of complete pathological response, nodal response, resection margin, anal preservation, anastomotic leak, local recurrence, distant recurrence, disease-free survival, and overall survival. RESULTS: There were 15 comparative studies with 2437 patients in the neoadjuvant chemoradiotherapy group and 2284 in the total neoadjuvant therapy group. The pooled complete pathological response was 22.3% in the total neoadjuvant therapy group, compared with 14.2% in the standard neoadjuvant chemoradiotherapy group (p < 0.001). Even though there was no difference in local recurrence rate, there was a significantly lower rate of distant recurrence (OR 0.81, p = 0.02), and better 3-year disease-free survival (70.6% vs. 65.3%, respectively, p < 0.001) and overall survival (84.9% vs. 82.3%, respectively, p = 0.006), favoring the total neoadjuvant therapy group. Due to significant heterogeneity in the study protocols, there remains uncertainty on the ideal chemotherapy/radiotherapy sequence. CONCLUSIONS: This study provides supporting evidence on the favorable immediate and intermediate oncological outcomes with the use of total neoadjuvant therapy for locally advanced rectal cancer.
BACKGROUND: Total neoadjuvant therapy in rectal cancer refers to the administration of chemoradiotherapy plus chemotherapy before surgery. Recent studies have shown improved pathological complete response and disease-free survival with this approach. However, survival benefits remain unproven. Our objective is to present a metaanalysis of oncological outcomes of total neoadjuvant therapy in locally advanced rectal cancer. PATIENTS AND METHODS: A comprehensive search was performed on PubMed, Medline, and Google Scholars. Studies comparing total neoadjuvant therapy with standard neoadjuvant chemoradiotherapy were included. Data extracted from the individual studies were pooled and a metaanalysis performed. The outcomes of interest are the rate of complete pathological response, nodal response, resection margin, anal preservation, anastomotic leak, local recurrence, distant recurrence, disease-free survival, and overall survival. RESULTS: There were 15 comparative studies with 2437 patients in the neoadjuvant chemoradiotherapy group and 2284 in the total neoadjuvant therapy group. The pooled complete pathological response was 22.3% in the total neoadjuvant therapy group, compared with 14.2% in the standard neoadjuvant chemoradiotherapy group (p < 0.001). Even though there was no difference in local recurrence rate, there was a significantly lower rate of distant recurrence (OR 0.81, p = 0.02), and better 3-year disease-free survival (70.6% vs. 65.3%, respectively, p < 0.001) and overall survival (84.9% vs. 82.3%, respectively, p = 0.006), favoring the total neoadjuvant therapy group. Due to significant heterogeneity in the study protocols, there remains uncertainty on the ideal chemotherapy/radiotherapy sequence. CONCLUSIONS: This study provides supporting evidence on the favorable immediate and intermediate oncological outcomes with the use of total neoadjuvant therapy for locally advanced rectal cancer.
Authors: Abu Bakar Hafeez Bhatti; Anum Waheed; Aqsa Hafeez; Ali Akbar; Aamir Ali Syed; Shahid Khattak; Ather Saeed Kazmi Journal: Asian Pac J Cancer Prev Date: 2015
Authors: Andrea M Guida; Bruno Sensi; Vincenzo Formica; Rolando M D'Angelillo; Mario Roselli; Giovanna Del Vecchio Blanco; Piero Rossi; Gabriella T Capolupo; Marco Caricato; Giuseppe S Sica Journal: Biol Direct Date: 2022-06-13 Impact factor: 7.173
Authors: K van den Berg; D P Schaap; E L K Voogt; T E Buffart; H M W Verheul; J W B de Groot; C Verhoef; J Melenhorst; J M L Roodhart; J H W de Wilt; H L van Westreenen; A G J Aalbers; M van 't Veer; C A M Marijnen; J Vincent; L H J Simkens; N A J B Peters; M Berbée; I M Werter; P Snaebjornsson; H M U Peulen; I G van Lijnschoten; M J Roef; G A P Nieuwenhuijzen; J G Bloemen; J M W E Willems; G J M Creemers; J Nederend; H J T Rutten; J W A Burger Journal: BMC Cancer Date: 2022-09-06 Impact factor: 4.638
Authors: Michael P Flood; Joseph C H Kong; Kasmira Wilson; Helen Mohan; Peadar S Waters; Jacob J McCormick; Satish K Warrier; Jeanne Tie; Robert Ramsay; Michael Michael; Alexander G Heriot Journal: Ann Surg Oncol Date: 2022-04-09 Impact factor: 4.339